Items Tagged ‘gemzar’

June 6th, 2016

A New Standard of Care of Treatment for Resectable Pancreatic Cancer?

By

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting the European Study Group for Pancreatic Cancer (ESPAC)-4 has presented results that will change the management of pancreatic cancer. Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the […]

View full entry

Tags: 2016, asco, capecitabine, ESPAC-4, European Study Group for Pancreatic Cancer, gemcitabine, gemzar, immunotherapy, mesothelin-directed cells, News, Pancreatic Cancer, Xeloda


December 23rd, 2015

Abraxane® Combo Promising in Triple Negative Breast Cancer

By

The chemotherapy combination consisting of Abraxane® (nab-paclitaxel) plus carboplatinum (carbo) improves outcomes compared with Abraxane plus Gemzar (gemcitabine) for triple negative breast cancer. These results were presented at the 2015 annual San Antonio Breast Cancer Symposium (SABCS). Approximately 10-20% of breast cancers are referred to as triple negative breast cancer (TNBC). These types of cancers […]

View full entry

Tags: abraxane, Breast Cancer, gemzar, News, tnbc, Triple Negative Breast Cancer


June 2nd, 2015

Combination of Iniparib, Gemzar®, and Carboplatin Active in Initial Treatment of Early-Stage Triple-Negative Breast Cancer

By

The combination of iniparib, Gemzar® (gemcitabine), and carboplatin appears promising in the initial treatment of patients with early-stage triple-negative breast cancer with a BRCA1/2 mutation. In addition, researchers have found ways to identify patients without a BRCA mutation who are likely to benefit. These findings were published in the Journal of Clinical Oncology. Breast cancers […]

View full entry

Tags: BRCA1/2 mutation, Breast Cancer, carboplatin, early-stage, gemzar, Iniparib, News, Stage I Node Negative Breast Cancer, Triple Negative Breast Cancer


September 23rd, 2014

Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer

By

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage, and treatment of advanced disease remains challenging. Gemzar has been a standard chemotherapy drug […]

View full entry

Tags: gemzar, gilead, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, simtuzuma, Stage IV Pancreatic Cancer


July 10th, 2014

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival

By

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (gemcitabine). These findings were recently published in Journal of Clinical Oncology. Pancreatic cancer is one of the deadliest forms […]

View full entry

Tags: eloxatin, gemzar, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer


July 1st, 2014

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy

By

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated patients with metastatic pancreatic cancer was presented recently at the annual American Society of Clinical Oncology meeting in Chicago.1  Results of the study were initially reported in the New England Journal of Medicine.2 Pancreatic cancer […]

View full entry

Tags: abraxane, gemzar, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer